A

Alto Neuroscience Inc
NYSE:ANRO

Watchlist Manager
Alto Neuroscience Inc
NYSE:ANRO
Watchlist
Price: 15.47 USD 0.98% Market Closed
Market Cap: $480.7m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
0
/
0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Alto Neuroscience Inc
NYSE:ANRO
480.7m USD
Loading...
IN
Aaswa Trading and Exports Ltd
BSE:512038
26.9T INR
Loading...
US
GE Vernova LLC
NYSE:GEV
193.6B USD
Loading...
UK
Eight Capital Partners PLC
F:ECS
158.4B EUR
Loading...
US
China Industrial Group Inc
OTC:CIND
121B USD
Loading...
US
Schlumberger NV
NYSE:SLB
72B USD
Loading...
US
Baker Hughes Co
NASDAQ:BKR
55.2B USD
Loading...
IN
GTV Engineering Ltd
BSE:539479
4.5T INR
Loading...
US
CoreWeave Inc
NASDAQ:CRWV
46.2B USD
Loading...
CH
Galderma Group AG
SIX:GALD
34.1B CHF
Loading...
US
Reddit Inc
NYSE:RDDT
34.2B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Alto Neuroscience Inc
Glance View

Market Cap
480.7m USD
Industry
N/A

Alto Neuroscience Inc is a US-based company operating in industry. The company is headquartered in Los Altos, California. The company went IPO on 2024-02-02. Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

ANRO Intrinsic Value
Not Available
A
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top